ARS PHARMACEUTICALS INC. - COMMON STOCK

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

22 2月 2023 15:05:01 条件 Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

09 2月 2023 05:30:00 条件 Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

10 11月 2022 07:00:03 条件 Nasdaq GlobeNewswire

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

08 11月 2022 15:02:00 条件 Nasdaq GlobeNewswire